Metabolic and oxidative status alterations induced in Ruditapes philippinarum exposed chronically to estrogen 17α-ethinylestradiol under a warming scenario.

Abstract

The presence of pharmaceuticals in the aquatic environment is an ongoing concern. However, the information regarding their effects under different climate change scenarios is still scarce. 17α-ethinylestradiol (EE2) is widely present in different aquatic systems showing negative impacts on aquatic organisms even when present at trace concentrations (≈1ng/L). Nevertheless, its impact on bivalves is poorly understood, especially considering the influence of climate change factors. This study aimed to assess the toxicological impacts of EE2 under current and predicted warming scenarios, in the edible clam Ruditapes philippinarum. For this, clams were exposed for 28 days to different EE2 concentrations (5, 25, 125, 625ng/L), under two temperatures (17 °C (control) and 21 °C). Drug concentrations, bioconcentration factors and biochemical parameters, related to oxidative stress and energy metabolism, were evaluated. Results showed that under actual and predicted temperature scenarios EE2 concentrations led to a disturbance in redox homeostasis of the clams, characterized by an increase in oxidized glutathione in contaminated organisms compared to control ones. Nevertheless, clams were capable to cope with the stressful conditions, activating their defence mechanisms (especially at the highest exposure concentration and in particular at increased temperature), and no oxidative damage occured. Although limited effects were observed, the present findings indicate that under both temperatures contaminated clams altered their biochemical performance, which can impair their sensitivity and protection capacity to respond to other environmental changes and/or affect their capacity to grow and reproduce. The results presented here highlight the need for further research on this thematic, considering that climate change is an ongoing problem, and the levels of some pharmaceutical drugs will continue to increase in marine/estuarine environments.